imatinib mesylate has been researched along with Signet Ring Cell Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, Y; Kario, K; Kubota, K; Shinozaki, T | 1 |
1 other study(ies) available for imatinib mesylate and Signet Ring Cell Carcinoma
| Article | Year |
|---|---|
Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer.
Topics: Carcinoma, Signet Ring Cell; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Rare Diseases; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies; Tomography, X-Ray Computed | 2017 |